NCT04117945 - Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 3, 2020

Primary Completion Date

September 5, 2023

Study Completion Date

March 31, 2025

Conditions

BRAF V600E NegativeKRAS Gene Mutation NegativeLocally Advanced Unresectable Colorectal AdenocarcinomaMetastatic Colorectal AdenocarcinomaNRAS Gene Mutation NegativeStage III Colorectal Cancer AJCC v8Stage IIIA Colorectal Cancer AJCC v8Stage IIIB Colorectal Cancer AJCC v8Stage IIIC Colorectal Cancer AJCC v8Stage IV Colorectal Cancer AJCC v8Stage IVA Colorectal Cancer AJCC v8Stage IVB Colorectal Cancer AJCC v8Stage IVC Colorectal Cancer AJCC v8

Interventions

BIOLOGICAL

Cetuximab

Given IV

DRUG

Irinotecan

Given IV

BIOLOGICAL

Panitumumab

Given IV

DRUG

Regorafenib

Given PO

Trial Locations (15)

15212

Allegheny General Hospital, Pittsburgh

20007

MedStar Georgetown University Hospital, Washington D.C.

27710

Duke University Medical Center, Durham

30322

Emory University Hospital/Winship Cancer Institute, Atlanta

32224

Mayo Clinic in Florida, Jacksonville

43623

Toledo Clinic Cancer Center, Toledo

51101

Siouxland Regional Cancer Center, Sioux City

52242

University of Iowa/Holden Comprehensive Cancer Center, Iowa City

53226

Aurora Cancer Care-Milwaukee West, Wauwatosa

55905

Mayo Clinic, Rochester

60637

University of Chicago Comprehensive Cancer Center, Chicago

67214

Cancer Center of Kansas, Wichita

68198

University of Nebraska Medical Center, Omaha

85259

Mayo Clinic in Arizona, Scottsdale

90033

USC / Norris Comprehensive Cancer Center, Los Angeles

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Academic and Community Cancer Research United

OTHER